Franklin Genomic Advancements ETF
ETFYour view on HELX
Franklin Genomic Advancements ETF
ETFFranklin TempletonSentiment
AUM (USD)
$29.84M
Expense Ratio
0.5%
Holdings
63
Sentiment
Overview for Franklin Genomic Advancements ETF
- Fund Type
- ETF
- Fund Issuer
- Franklin Templeton
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- February 25, 2020
- Domicile
- US
- Fund Type
- ETF
- Fund Issuer
- Franklin Templeton
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- February 25, 2020
- Domicile
- US
- Fund Type
- ETF
- Fund Issuer
- Franklin Templeton
- Asset Class
- Equity
- Sector
- Financial Services
- Industry
- Asset Management
- Inception Date
- February 25, 2020
- Domicile
- US
About this fund
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emergin…
HELX Stock Price
Key Facts
EquityExpense Ratio
0.5%
AUM
$29.84M
Fund Details
Expense Ratio
0.5%
Assets Under Management
$29.84M
NAV
$39.79 USD
Holdings
63
Average Volume
1.7K
Inception Date
February 25, 2020
Asset Class
Equity
Fund Issuer
Franklin Templeton
Domicile
US
ISIN
US35473P5200
CUSIP
35473P520
NAV Currency
USD
Expense Ratio
0.5%
Assets Under Management
$29.84M
NAV
$39.79 USD
Holdings
63
Average Volume
1.7K
Inception Date
February 25, 2020
Asset Class
Equity
Fund Issuer
Franklin Templeton
Domicile
US
ISIN
US35473P5200
CUSIP
35473P520
NAV Currency
USD
Latest headlines and company announcements for this company. Press releases and market coverage, newest first.
News
this company valued side by side against its closest peers. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.